News >

Emerging Agents Offer Hope in Late Relapse Myeloma

Caroline Seymour
Published: Thursday, Oct 11, 2018

Sandy W. Wong, MD

Sandy W. Wong, MD
Patients in late relapse comprise one of the largest unmet needs in multiple myeloma, said Sandy Wong, MD, but added that monoclonal antibodies and antibody-drug conjugates (ADCs) are the biggest potentially practice-changing agents in this setting.

State of the Science Summit™ on Hematologic Malignancies, Wong discussed emerging agents being explored for the treatment of patients with multiple myeloma in late relapse.

OncLive: What are some of the agents being explored for patients in late relapse?

Wong: There are a lot of clinical trials being studied in that population right now. It is also the population of greatest unmet medical need. The first trial I went over was a daratumumab-based trial. Daratumumab has been used in multiple different combinations in both the newly diagnosed as well as in the relapsed setting.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x